Body mass index in patients with moderate‐to‐severe psoriasis in Spain and its impact as an independent risk factor for therapy withdrawal: results of the Biobadaderm Registry

Carrascosa, J.M.; Vilavella, Marta; García‐Doval, I.; Carretero, G.; Vanaclocha, F.; Daudén, E.; Gómez-García, F.J.; Herrera‐Ceballos, Enrique; Dobao, P. de la Cueva; Belinchón, Isabel; Sánchez‐Carazo, J.L.; Alsina, M.; López-Estebaranz, J.L.; Ferrán, Marta; Peral, Fernando Zamanillo; Torrado, R.; Rivera, R.; Jiménez‐Puya, R.; Mendiola, M.; Ferrándiz, Carlos

doi:10.1111/jdv.12208

Cited by 67 publications

(46 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…26,27 Importantly, there is evidence that overweight is associated with a loss of efficacy of anti-TNF agents. 28 The present manuscript confirms this finding and supports the importance of an adequate management of obesity in the treatment of psoriasis. To our knowledge, our study provides the first evidence that nail involvement and the erythrodermic phenotype are bad prognosis factors for anti-TNF treatment.…”

Section: Discussionsupporting

confidence: 93%

Association of the PDE3A-SLCO1C1 locus with the response to anti-TNF agents in psoriasis

Juliá¹,

Ferrándiz

Daudén

et al. 2014

Pharmacogenomics J

View full text Add to dashboard Cite

Psoriasis is a prevalent autoimmune disease of the skin that causes significant psychological and physical disability. Tumor necrosis factor (TNF)-blocking agents have proven to be highly efficacious in the management of moderate-to-severe psoriasis. However, a significant percentage of patients do not respond to this treatment. Recently, variation at the PDE3A-SLCO1C1 (phosphodiesterase 3A-SoLute Carrier Organic anion transporter family member 1C1) locus has been robustly associated with anti-TNF response in rheumatoid arthritis. Using a cohort of 130 psoriasis patients treated with anti-TNF therapy, we sought to analyze the association of this locus with treatment response in psoriasis. We found a highly significant association between PDE3A-SLCO1C1 and the clinical response to TNF blockers (P=0.0031). Importantly, the allele that was previously associated with the lack of response to rheumatoid arthritis (G allele, single-nucleotide polymorphism rs3794271) was associated with a higher anti-TNF efficacy in psoriasis. The results of this study are an important step in the characterization of the pharmacogenetic profile associated with anti-TNF response in psoriasis.

show abstract

Section: Discussionsupporting

confidence: 93%

Association of the PDE3A-SLCO1C1 locus with the response to anti-TNF agents in psoriasis

Juliá¹,

Ferrándiz

Daudén

et al. 2014

Pharmacogenomics J

View full text Add to dashboard Cite

show abstract

“…Interestingly, BMI was positively correlated with the frequency of ADR in patients with PsV, but negatively correlated with the incidence of ADR in patients with PsA. These results are consistent with a previous report on the analysis of the impact of BMI in patients with moderate to severe PsV in Spain, which showed that overweight to obesity was associated with a 17% increased risk of having an adverse event (hazard ratio, 1.17; 95% confidence interval, 1.02–1.36) 18. On the other hand, it is possible that PsA patients with lower BMI have a greater risk of adverse events, as previously reported in rheumatoid arthritis patients 19.…”

Section: Discussionsupporting

confidence: 90%

Safety and efficacy of adalimumab treatment in Japanese patients with psoriasis: Results of SALSA study

Asahina

Torii

Ohtsuki

et al. 2016

The Journal of Dermatology

View full text Add to dashboard Cite

The safety and efficacy of adalimumab were evaluated over 24 weeks in Japanese patients with psoriasis in routine clinical practice. In this multicenter, observational, open‐label, postmarketing study, primary efficacy measures included the Psoriasis Area and Severity Index (PASI) and the Dermatology Life Quality Index (DLQI) in all patients with psoriasis. In patients with psoriatic arthritis (PsA), the 28‐joint Disease Activity Score (DAS28) and the visual analog scale (VAS) pain were also evaluated. Safety was assessed based on the frequency of adverse drug reactions (ADR). Among patients with psoriasis evaluated for efficacy (n = 604), significant improvements from baseline were observed in mean PASI and DLQI scores at weeks 16 and 24 (all P < 0.0001). Furthermore, in psoriasis patients without PsA, the PASI 75/90 response rates were 55.9%/28.4% at week 16 (n = 306) and 65.6%/43.3% at week 24 (n = 270), respectively. In patients with PsA evaluable for effectiveness, significant improvements from baseline were observed in PASI, DAS28 erythrocyte sedimentation rate, DAS28 C‐reactive protein and VAS pain at weeks 16 and 24 (all P < 0.0001). ADR and serious ADR were reported by 26.1% and 3.3%, respectively, of 731 safety evaluable patients with psoriasis; no unexpected safety findings were noted. The safety profile and effectiveness of adalimumab for the treatment of psoriasis in a routine clinical setting were as expected in Japanese patients.

show abstract

“…Obese patients were less likely to be long-term PASI90 responders than patients with BMI <30. Interestingly, the prevalence of obesity in our cohort was similar in men (12/42, 28.6%) and women (6/25, 24%), and consistent with the prevalence in a Spanish registry of patients with psoriasis under systemic or biological treatment (28.7%) [9]. On multivariate analysis, only BMI <30 was associated with the PASI90 response at 2 years.…”

Section: Discussionsupporting

confidence: 54%

“…On the other hand, the drug survival of ustekinumab in our series (30.5 months, median 36) ranks with the shortest (adalimumab, mean 34.7 months) in an Italian multicenter series reflecting routine clinical practice with anti-TNF agents in the treatment of psoriasis [16]. We have not been able to confirm in our patients treated with ustekinumab the association between obesity and overall diminished drug survival that has been detected in the BIOBADADERM Spanish registry [9]. Multivariate analysis using Cox's regression model showed the only variable significantly associated with increased probability of drug survival to be PASI75 response at week 28 (hazard ratio 4.9).…”

Section: Discussioncontrasting

confidence: 39%

Long-Term Efficacy, Safety and Drug Survival of Ustekinumab in a Spanish Cohort of Patients with Moderate to Severe Plaque Psoriasis

Puig¹,

Ruiz‐Salas²

2015

Dermatology

View full text Add to dashboard Cite

Objective: To investigate the efficacy and safety of ustekinumab in clinical practice and the influence of several variables on response rates as well as on drug survival. Methods: Retrospectively collected efficacy and safety data of a cohort of 67 consecutive patients treated with ustekinumab for moderate to severe psoriasis for at least 28 weeks and a maximum of 3 years. Drug survival was analyzed by the Kaplan-Meier method with log-rank test. Results: PASI75 response rates were numerically higher in patients treated with 45 mg and patients naïve to tumor necrosis factor (TNF)-blocking agents, at all time points. Drug survival was not significantly affected by any variable. Conclusion: Male sex, weight >100 kg, obesity, and previous failure of one or more TNF inhibitors were associated with a diminished response to treatment. Obesity or previous exposure to anti-TNF agents was not associated with a diminished drug survival in this Spanish cohort.

show abstract

Body mass index in patients with moderate‐to‐severe psoriasis in Spain and its impact as an independent risk factor for therapy withdrawal: results of the Biobadaderm Registry

Abstract: Patients with moderate-to-severe psoriasis had a higher prevalence of obesity than the general population. Increased BMI was associated with an increased risk of treatment discontinuation due to lack of effectiveness and a higher risk of adverse events.

Cited by 67 publications

References 23 publications

Association of the PDE3A-SLCO1C1 locus with the response to anti-TNF agents in psoriasis

Association of the PDE3A-SLCO1C1 locus with the response to anti-TNF agents in psoriasis

Safety and efficacy of adalimumab treatment in Japanese patients with psoriasis: Results of SALSA study

Long-Term Efficacy, Safety and Drug Survival of Ustekinumab in a Spanish Cohort of Patients with Moderate to Severe Plaque Psoriasis

Contact Info

Product

Resources

About